Galena Biopharma is focused
on discovering, developing, and commercializing innovative therapies addressing
major unmet medical needs using targeted biotherapeutics.
Abstral, the Company’s
sublingual formulation of fentanyl citrate, provides statistically significant
and rapid relief of breakthrough cancer pain for patients with all types of
cancer, providing improvements in pain-related daily function and patient
quality of life. Currently in clinical trials, though, is NeuVax (neliepimut-S
or E75), one of Galena’s cancer immunotherapy treatments.
The immunotherapy of cancer
aims at specifically activating cells of the immune system, especially the
so-called cytotoxic T-cells (“killer T-cells”) to seek out and eliminate tumor
cells while not harming healthy tissue.
NeuVax works by turning on
the immune system. It recruits the main components of the cellular immune
system to fight cancer by presentation of a T-cell peptide epitope in the
context of the peptide-HLA-T-cell receptor complex–effectively using the
patient’s own immune system (i.e., nature’s own defense system against foreign
or harmful germs) for the treatment of the cancer.
Folate Binding Protein-E39
(FBP), another Galena treatment, is a targeted vaccine aimed at preventing the
recurrence of ovarian, endometrial, and breast cancers. It has very limited
tissue distribution and expression in non-malignant tissue making it an ideal
immunotherapy target.
The FBP vaccine consists of
the E39 peptide derived from the folate binding protein combined with the
immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF), and
is specifically used to treat endometrial and ovarian cancers.
Ideally, a vaccine is
specific and should only affect the cancer cells and not attack normal cells.
Cancer immunotherapy causes the immune system to make antibodies to one or
several specific antigens, and/or make killer T cells to attack cancer cells that
express those antigens. Similar to prophylactic vaccines, Galena’s cancer
immunotherapies can be delivered with adjuvants, which are designed to boost
the immune response.
For more information, visit
the website at www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
